Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System

Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System Purpose of ReviewBreast Ductal Carcinoma in Situ (DCIS) is an increasingly common diagnosis and already accounts for ~20% of screen-detected breast cancers. A subset of patients with DCIS will experience disease recurrence and some will die from breast cancer. Tailored strategies for treatment are lacking at this time. Human Epidermal Growth Factor Receptor 2 (HER2) is a tumor associated antigen that is shown to correlate with poorer outcomes among patients with early breast cancer, including DCIS. Significant interactions between the humoral and cellular branches of the immune system were observed in tumorigenesis of HER2-expressing lesions. These can be leveraged through administration vaccines to improve outcomes among patients with HER2+ DCIS.Recent FindingsPre-clinical and clinical data support that immune response supported not only by CD8+ cytotoxic T cells but also CD4+ helper T cells can lead to antitumor activity in DCIS. These early studies have demonstrated prolonged, broad, activation of the immune system, and with a favorable toxicity profile.SummaryAs nuances in our understanding of immune responses to early breast cancer begin to unveil, there is growing momentum in the development of preventative strategies. Clinical trials assessing the efficacy of vaccines for the treatment of DCIS are forthcoming. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System

Loading next page...
 
/lp/springer-journals/treatment-from-within-ductal-carcinoma-as-an-opportunity-to-harness-vCPGYtvq3H
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00356-1
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewBreast Ductal Carcinoma in Situ (DCIS) is an increasingly common diagnosis and already accounts for ~20% of screen-detected breast cancers. A subset of patients with DCIS will experience disease recurrence and some will die from breast cancer. Tailored strategies for treatment are lacking at this time. Human Epidermal Growth Factor Receptor 2 (HER2) is a tumor associated antigen that is shown to correlate with poorer outcomes among patients with early breast cancer, including DCIS. Significant interactions between the humoral and cellular branches of the immune system were observed in tumorigenesis of HER2-expressing lesions. These can be leveraged through administration vaccines to improve outcomes among patients with HER2+ DCIS.Recent FindingsPre-clinical and clinical data support that immune response supported not only by CD8+ cytotoxic T cells but also CD4+ helper T cells can lead to antitumor activity in DCIS. These early studies have demonstrated prolonged, broad, activation of the immune system, and with a favorable toxicity profile.SummaryAs nuances in our understanding of immune responses to early breast cancer begin to unveil, there is growing momentum in the development of preventative strategies. Clinical trials assessing the efficacy of vaccines for the treatment of DCIS are forthcoming.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jun 17, 2020

There are no references for this article.